Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.81 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808154 | 0.94 | PPARG (0.75) | PPARGSLC6A7MEN1KMT2AHRH4 | |
| SCHEMBL2809842 | 0.90 | PPARG (1.00) | PPARGPPARAHRH4MAPT | |
| SCHEMBL2806770 | 0.89 | PPARG (0.74) | PPARGMEN1KMT2AGAAMAPT | |
| SCHEMBL2804637 | 0.89 | PPARG (0.81) | PPARGPPARAHRH4MAPT | |
| SCHEMBL2805810 | 0.87 | PPARG (1.00) | PPARGPPARAHRH4 | |
| SCHEMBL2809044 | 0.87 | PPARG (1.00) | PPARGPPARAHRH4 | |
| SCHEMBL2810965 | 0.87 | PPARG (1.00) | PPARGSLC6A7PPARAHRH4 | |
| SCHEMBL2805809 | 0.87 | PPARG (0.87) | PPARGMEN1KMT2APPARAHRH4 | |
| SCHEMBL2812228 | 0.87 | PPARG (1.00) | PPARGPPARAHRH4 | |
| SCHEMBL2807152 | 0.85 | PPARG (0.92) | PPARGPPARAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARD, PPARG | PPARG 3/4885SLC6A7 412/4885MEN1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.